Biomea Fusion, Inc. (BMEA) stock
Close on Nov 12, 2026Market cap $40.79MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $40.79M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.38
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$22.31M
- EPS, diluted
- -$1.18
- Book value per share
- $0.10
- Diluted shares
- 73M
Trading
- Previous close
- $0.61
- Open
- $0.61
- Day's range
- $0.56 – $0.63
- Volume
- 839,262
- Average volume (20 days)
- 1,464,563
- Beta (5 years)
- 0.82
- 52-week range
- $0.54 – $2.24
- RSI (14 days)
- 33.8
- Volatility (1 year)
- 92.4%
- Relative volume
- 0.40×
- WACC
- 9.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BMEA | S&P 500 | Difference | BMEA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -58.6% | -2.7% | −55.9 pts | ||
| 3 months | -56.0% | -1.7% | −54.3 pts | ||
| Year to date | -54.6% | +11.9% | −66.5 pts | ||
| 1 year | -58.9% | +12.0% | −70.9 pts | ||
| 3 years | -93.4% | +78.2% | −171.6 pts | -59.5% | +21.2% |
| 5 years | -95.3% | +73.2% | −168.5 pts | -45.6% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biomea Fusion filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Results
- Update
About Biomea Fusion
Pharmaceutical Preparations
Biomea Fusion is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule therapies for metabolic conditions. The organization focuses on treatments for type 1 diabetes, type 2 diabetes, and obesity. Its research pipeline centers on two core investigational programs: icovamenib, an oral covalent menin inhibitor under study for diabetes and obesity, and BMF-650, an oral glucagon-like peptide-1 receptor agonist in development for obesity. The company has no commercialized products, and its investigational therapies target patient populations suffering from diabetes and metabolic disorders.
Company profile, executives and historyBiomea Fusion stock: common questions
What is Biomea Fusion's stock price?
BMEA closed at $0.56 on Nov 12, 2026, down 7.89% on the day. Over the past 52 weeks it traded between $0.54 and $2.24.
What is Biomea Fusion's market cap?
Biomea Fusion was worth $40.79M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BMEA's P/E ratio?
Biomea Fusion lost money over fiscal 2025 (diluted EPS -$1.18), so it has no meaningful P/E ratio.
Does Biomea Fusion pay a dividend?
No. Biomea Fusion has not paid a cash dividend over the last twelve months.
How has BMEA stock performed over the past year?
Including dividends, BMEA returned -58.9% over the past year, against +12.0% for the S&P 500.
How many BMEA shares are sold short?
15M shares were sold short at the latest FINRA report, 22.21% of the float, or 8.4 days of average trading volume.
Who are Biomea Fusion's competitors?
Companies most similar to Biomea Fusion by business, industry and size include MTVA, VTVT, MBX, SEPN, GPCR.
See a number that looks wrong?